TL;DR
Get pet supplies delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
The FDA issued an Emergency Use Authorization on Nov. 3 for Bravecto (fluralaner) chewable tablets to treat New World screwworm infestations in dogs and puppies. The agency says the authorization rests on scientific evidence that the drug may be effective when used as directed, with potential benefits outweighing known and potential risks.
The U.S. Food and Drug Administration issued an Emergency Use Authorization on Nov. 3 for Bravecto (fluralaner) chewable tablets to treat New World screwworm infestations in dogs and puppies. The authorization applies to myiasis, an infestation by fly larvae, and comes as animal-health officials monitor confirmed detections of the pest.
The FDA said the authorization is based on scientific evidence indicating fluralaner may be effective when used as directed. The agency determined that the drug’s potential benefits outweigh its known and potential risks for this emergency use. That finding supports the authorization, but the supplied report does not provide study results, effectiveness rates, or further details about the evidence considered.
Bravecto is a chewable tablet containing fluralaner, an antiparasitic in the isoxazoline class. The FDA had previously approved the product to treat flea and tick infestations in dogs. The new authorization covers treatment of New World screwworm infestations in dogs and puppies; it is distinct from the product’s earlier flea-and-tick uses.
The report advises monitoring dogs that live in or travel to areas with confirmed cases. Possible signs include visible maggots or a foul odor from wounds or body openings. It directs readers to the U.S. Department of Agriculture’s dashboard of confirmed New World screwworm detections for current U.S. case information.
A New Emergency Treatment Option
The authorization gives veterinarians and dog owners an additional treatment option for a parasitic infestation that can affect animal health. Its practical relevance is greatest for dogs in, or traveling through, locations where cases have been confirmed. The FDA’s decision is specific to emergency use for NWS in dogs and puppies; it does not change the product’s established flea-and-tick indication described in the report.
For owners, the immediate implication is vigilance rather than assuming all dogs face the same level of risk. The source says exposure risk remains low for most U.S. dogs, while recommending monitoring in areas with confirmed detections. The authorization also does not remove the need for veterinary assessment: suspected infestations should be discussed with a veterinarian, who can determine appropriate care for the individual animal.
Products Worth Considering
PetSafe Electronic Pet Door with Collar Key Sensor, Large
Shark Pet Cordless Stick Vacuum, Up to 40-Minute Runtime, Ocean Blue, IX141
Shark IQ Robot Self-Empty XL Vacuum, RV1001AE
As an affiliate, we earn on qualifying purchases.
Bravecto’s Existing Veterinary Use
Fluralaner belongs to a class of antiparasitic drugs used in dogs. Before this emergency authorization, the FDA had approved Bravecto chewable tablets for treatment of flea and tick infestations in canine patients. The Nov. 3 action adds an emergency-use purpose for the product in the specific setting of New World screwworm myiasis.
New World screwworm is tracked through confirmed detections reported by the U.S. Department of Agriculture. The source material does not give a case count, geographic breakdown, or a trend over time, so it does not support conclusions about how widespread the current risk is. Owners can consult the USDA dashboard for up-to-date U.S. detections.
Evidence and Case Details Not Provided
The source report does not identify the year of the Nov. 3 authorization, describe the studies supporting the FDA’s decision, or state how many dogs were included in the evidence. It also gives no treatment success rate, detailed use instructions, or information about possible adverse events beyond noting that the FDA weighed known and potential risks against potential benefits.
The report does not specify the geographic extent or number of confirmed detections, nor does it describe how long the emergency authorization will remain in effect or whether additional regulatory action is expected. Those details cannot be inferred from the authorization announcement alone.
Monitor USDA Detection Updates
The next practical step for owners in affected or potentially affected areas is to monitor USDA updates on confirmed New World screwworm detections and watch dogs for the signs cited in the report. Anyone who suspects an infestation should contact a veterinarian for assessment and guidance on care.
Further information about the authorization’s evidence, its terms, and any later regulatory decisions would need to come from FDA updates or additional reporting. The source material does not announce a timetable for such updates.
Key Questions
What did the FDA authorize?
The FDA issued an Emergency Use Authorization for Bravecto (fluralaner) chewable tablets to treat New World screwworm infestations, or myiasis, in dogs and puppies.
When was the authorization issued?
The report says it was issued on Nov. 3, but does not specify the year.
Does this replace Bravecto’s flea-and-tick approval?
No. The report says Bravecto was previously approved for flea and tick treatment in dogs. The emergency authorization adds use for New World screwworm infestations in dogs and puppies.
What signs should dog owners watch for?
The report lists visible maggots and a foul odor in wounds or body openings. Owners concerned about a possible infestation should contact a veterinarian.
Where can owners check for confirmed cases?
The report points to the U.S. Department of Agriculture’s dashboard of confirmed New World screwworm detections for current U.S. case information.
Source: veterinarypracticenews.com
